Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CEOCAST this weekend:
Advanced Cell Technology, Inc. (OTCBB: ACTC), a leader in regenerative medicine, announced 2011 first quarter results last week. ACTC reported a net loss of $3.3 million for the 2011 first quarter. During the first quarter, ACTC made significant progress in securing sites to conduct their Phase I/II clinical trials for Stargardt’s Macular Dystrophy (SMD) and Dry Age-related Macular Degeneration (Dry AMD). ACTC recently announced UCLA Institutional Review Board (IRB) Approval of its Phase I/II clinical trials at the UCLA Jules Stein Institute in Los Angeles. ACTC also recently filed a clinical trial application with European Medicines and Healthcare products Regulatory Agency (MHRA) seeking clearance to initiate a similar SMD trial in Europe. With the existing cash on hand as well as access to capital, ACTC has the financial strength to complete the Phase I/II trials. ACTC stock gained another $0.01 for the third straight week to close at $0.21.
Monthly Volume Report:
December 2010: 1,221,572,570
January 2011: 486,703,185
Febuary 2011: 131,975,926
March 2011: 217,573,449
April 2011: 168,851,054
http://www.otcbb.com/asp/tradeact_mv.asp?SearchBy=issue&Issue=ACTC&SortBy=volume&Month=4-1-2011&IMAGE1.x=17&IMAGE1.y=3
ACTC on CEOCAST:
Advanced Cell Technology, Inc. (OTCBB: ACTC), a leader in regenerative medicine, should benefit from a Federal Appeals Court ruling allowing continued federal funding of Embryonic Stem Cell research. In a statement issued by interim chairman and CEO of ACTC, Gary Rabin, the company addresses how the ruling could provide a tremendous boost to the regenerative medicine industry and how ACTC will continue to work with the National Institutes of Health toward securing approval for federal funding of their embryonic stem cell lines derived without damaging the embryo, using their blastomere technique. ACTC’s blastomere technique directly addresses the moral questions that prompted the Bush Administration to cut funding for stem cell research, and ACTC’s stem cell lines have been determined to be of the highest quality. As a result, ACTC is in a better position to obtain federal funding than others using techniques to derive their stem cell lines that would damage or destroy the embryo. ACTC was recently granted approval for their first ever human clinical trials using embryonic-derived stem cells to treat Stargardt’s Macular Dystrophy (SMD) and Dry Age-related Macular Degeneration (AMD). Last week, UCLA’s Jules Stein Eye Institute was announced as a site for ACTC’s Phase I/II trials for SMD and AMD. ACTC’s share price continued its climb last week, rising another $0.01 to close at $0.20 a share.
This makes sense. Some MM started following this on Friday May 6th.
Lowest short volume:
20110506|ACTC|797017|0|7302918|O
http://regsho.finra.org/FORFshvol20110506.txt
cty, I agree with you MM wants to keep the price low.
rocky301, IMHO MM specially Etrade played with it by increasing the ask volume. In 20 cents stock 2480 ask and 500 bid does not make any much of a difference! But it does trigger sell signal.
Net Loss $3,342,037 in 1st Q 2011 compared to $17,849,633 1st Q 2010.
This is the first time pps went up on 10Q release day!!
UCLA is getting grant for the RPE trial:
www.cirm.ca.gov/RFA/pdf/rfa_07-03/FA1-00616-1.pdf
Very soon ACTC lines will be approved for federal funding!
http://grants.nih.gov/stem_cells/registry/pending.htm?sort=orga
Our system posted WAIT . The previous SELL recommendation that was confirmed was made on 04.08.2011 (20) days ago, when the stock price was 5.5400 . Since then UNIS has fallen -0.54% .
UNIS at Americanbulls:
Our system posted WAIT . The previous SELL recommendation that was confirmed was made on 04.08.2011 (13) days ago, when the stock price was 5.5400 . Since then UNIS has fallen -9.75% .
http://www.americanbulls.com/weekly/StockPage.asp?CompanyTicker=UNIS&MarketTicker=NASD&Typ=S
UNIS Sell Confirmed on Americanbulls:
http://www.americanbulls.com/StockPage.asp?CompanyTicker=UNIS&MarketTicker=NASD&TYP=S
Who will be the Target?
There is no profit in these syringes: 11.99 for box of 100.
http://www.vereburn.com/index.php?main_page=product_info&cPath=85_1289&products_id=15901
Let us not talk about it till budget is approved. Keep figures crossed till then! Let it be a good surprise!
Matt mentioned something about it in the CC.
CEOAA1US,
These Patents are still assigned to Unitract Pty. Ltd. and not Unilife Corporation (UNIS).
UNIS has a present market cap of about 300 ml and they are raising another 200 ml to take care of intellectual property.
UNILIFE CORPORATION
$200,000,000
Common Stock, Preferred Stock,
Debt Securities, Warrants and Units
and
2,868,934 Shares of Common Stock
Don't believe me? Here is the link:
http://www.sec.gov/Archives/edgar/data/1476170/000095012311031173/y90007sv3.htm#Y90007102
http://www.americanbulls.com/weekly/StockPage.asp?CompanyTicker=UNIS&MarketTicker=NASD&Typ=S
UNIS Sell Confirmed on Americanbulls:
http://www.americanbulls.com/weekly/StockPage.asp?CompanyTicker=UNIS&MarketTicker=NASD&Typ=S
Another week of delay:
http://www.sciencefriday.com/blog/2011/03/uncertain-politics-and-uneasy-scientists/
There are two possible options for science to prevail. First, the courts can rule in favor of the new Obama legislation. Second, the new budget can simply leave out the Dickey-Wicker amendment, therefore making the entire court case irrelevant. Until then, those suffering from soon-to-be-curable diseases will just have to wait.
That means there will be two proxies and not 450, it does not make sense.
gebba54, Thanks!!
Paulness,
As per Washington Post story "It is too soon to tell whether the cells were helping T.J., Angela Atchison said." “They said it would be about a year before they’ll know if there’s any difference — if it takes,”
CEOA1US, Unilife has no patent or patent application.
No patent application:
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=unilife&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01
No Patent:
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Unilife&FIELD1=ASNM&co1=AND&TERM2=&FIELD2=&d=PTXT
Patent Collection of BD:
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Becton&FIELD1=ASNM&co1=AND&TERM2=Dickinson&FIELD2=ASNM&d=PTXT
Applications from BD:
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=0&p=1&f=S&l=50&Query=AN%2FBecton+AND+AN%2FDickinson&d=PG01
Let me know if I am doing something wrong!!
Why Unilife is tanking?
12/435,652 UNIVERSAL SAFETY SYRINGE Patent issued today to Mahurkar, Sakharam patent N0. 7918821
CEOCAST:
Volume Alert: Shares of Advanced Cell Technology Inc. (OTCBB: ACTC) surged 18% last week, possibly in anticipation of the company unveiling details on its Phase I/II trials scheduled to begin this year in Stargardt’s Macular Dystrophy and Dry AMD. ACTC closed this week at $0.192 which is up 13% from last week’s close of $0.166 a share.
Weekly buy confirmed on Americanbulls:
http://www.americanbulls.com/weekly/StockPage.asp?CompanyTicker=ACTC&MarketTicker=OTC&Typ=S
I am holding 500000 since July 2008.
Rocket301, Great Post!! Five Stars *****. Thank you.
That will change by Friday.
johan31, Thank you!!
Americanbulls: MCET Sell Confirmed: http://www.americanbulls.com/StockPage.asp?CompanyTicker=MCET&MarketTicker=OTC&Typ=S
johan31, where is the PR from ACTC on this Patent?
ACTC still Strong Buy:
http://www2.barchart.com/quotes/stocks/ACTC
ACTC received this Patent on March 22, but did not PR. I was expecting PR:
United States Patent 7,910,369
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=7910369&OS=7910369&RS=7910369
ACTC has already licensed part of it to Bi-Time and Lifeline Cell Technology.
Human part of the patent is still in the work.